Get your own press room

Receive news from us
16/06-09   -   Press releases

Research and Markets: In 2008, the Export Amounts of Chinese Raw Material Medicines Totalled 18 Billion USD Says the 2009 Research Report on Chinese Chemical Pharmaceuticals Industry

Research and Markets (http://www.researchandmarkets.com/research/cdf061/research_report_on) has announced the addition of the "Research Report on Chinese Chemical Pharmaceuticals Industry, 2009" report to their offering.

The chemical pharmaceuticals industry is the largest sub-sector of Chinese pharmaceuticals industry. In 2008, the sales revenues of Chinese chemical raw material medicines were 26.5 billion USD and the sales revenues of the chemical preparation industry were 3.34 billion USD, with the average growth rate all exceeding 20%. In 2008, China produced 2.2853 million tons chemical raw material medicines accumulatively, YOY up by 0.85% with the growth rate down by 15.05% compared with the same period of last year.

Because of the rigid demands for the pharmaceuticals, the influences of the international financial crisis on the pharmaceuticals industry were limited. In 2008, the export amounts of Chinese raw material medicines totalled 18 billion USD. From the aspect of the export volumes of the raw material medicines, the previous leading mass raw material medicines have been the major export variety in the international market so far. Because of the price advantage of the raw material medicines in the international market, it is predicted that the exports of Chinese raw material medicines will hold the line in 2009 to 2010.

In 2008, the export volumes of the Penicillin-G totaled 12 thousand tons, holding the line compared with 2007, but the average export price was increased. In 2009, with the influences of the grain price growth, the production costs were increased. Therefore, the major international manufacturers of semi-compound Penicillin-G will probably accelerate the import volumes of Chinese Penicillin-G.

According to the statistics, the accumulative export volumes of various tetracycline raw material medicines were 14 thousand tons in 2008 in China, exceeding the Penicillin-G in volume and standing the largest export raw material medicine variety in China. With the gradual discovery of the new uses of the tetracycline and the derivatives in the international pharmaceuticals field, the tetracycline antibiotics will not come to an end with the spring-up of the cefa-antibiotics just like what people predict. Conversely, the tetracycline and the derivatives will take certain place tightly in the international pharmaceuticals market (the tetracycline antibiotics are also can be used as the additives of the animal feed stuffs, there is large demands in the international market). It is predicted that the tetracycline will be one of the major export raw material medicine varieties in the next several years, with the export volumes exceeding ten thousand tons.

Cephalosporin is the leading antibiotics in the international pharmaceuticals market. At present, the best-sellers conclude 20 varieties, 80% of which can be produced in China. In 2008, China totally exported about 500 tons, in which ceftriaxone sodium accounted for 40%. A new export characteristic of Chinese cephalosporin is the export growth of the cefaclor. From the part of the cost performance ratio, cefaclor is the commendable common antibiotics in the clinical experiments, meanwhile, the domestic producing technologies have been mature and many technology indicators have few differences with the international advanced level. In consideration of the work force and cost advantages, many overseas manufacturers set up the cephalosporin production bases in China and produced the export cephalosporin raw material products.

China is the biggest producing and exporting country of the antipyretic analgesic products, the three largest export products including aspirin, paracetamol and Ibuprofen as well as Naproxen Sodium, Diclofenic Sodium and Analgin DAB. The respective export volumes of paracetamol, aspirin and Ibuprofen were 48.9 thousand tons, 30 thousand tons and 10 thousand tons in 2008. Because of the low prices, many countries including Europe and India put forward anti-dumping accusation of Chinese mass export antipyretic analgesic products, making Chinese export enterprises in the passive position.

The hot vitamin varieties in the international market were as follows: first, the natural vitamin E which was extracted from the vegetable oil trash, the demands exceeding the supplies for a long time in the international market. It was understood that the export volumes of the natural vitamin E in Zhejiang had been to 5 hundred tons with the export price 60% higher than the compound VE; second, the vitamin H which had been discovered with the new use of health care, for example, it could be processed into hypoglycemic compound agent together with chromium preparation. Therefore, the export would be increased. The export volumes of Chinese vitamin H accounted for 45% in the international market.

The export medicines against the cardiovascular disease can be divided into two parts: one is the depressor and the other is anti-lipemic agents. The statistics showed that the growth rate of the depressor and anti-lipemic agents was increased greatly, especially the best-sellers of statins, prils and sartans, which had been the major export raw material medicines against the cardiovascular disease in the international market.

In 2008, the export volumes of the statins totaled 500 tons. China had been capable of producing 8 to 9 varieties of the statin raw material medicines. Some multinational pharmaceuticals enterprises intended to produce the statin raw material medicines in China and then the products exported to European and American for the preparation production.

More following information can be obtained in this report:

* Present Development Situation of Chinese Chemical Pharmaceuticals Industry
* Policy Environments for the Development of Chinese Chemical Pharmaceuticals Industry
* Imports and Exports of Chinese Chemical Pharmaceuticals Industry
* Major Enterprises and Their Operations of Chinese Chemical Pharmaceuticals Industry
* Factors affecting the Development of Chinese Chemical Raw Material Medicine Industry
* Influences of International Financial Crisis on Chinese Chemical Pharmaceuticals Industry
* Investment Opportunities of Chinese Chemical Pharmaceuticals Industry
* Development Trends of Chinese Chemical Pharmaceuticals Industry

For more information visit http://www.researchandmarkets.com/research/cdf061/research_report_on

Press contacts


Company

Research and Markets
Guinness Centre, Taylors Lane
Dublin 8, England

  +353-1-481-1716


Receive news from Research and Markets by mail

Sign up here
Tell and spread your story with MyPressWire and expose them in your own unique online pressroom. Get started right away!
GK
danmarks kulturarv
thermex
iRobot
Witt
ret raad advokater